Myriad Genetics
MYGN
MYGN
260 hedge funds and large institutions have $2.22B invested in Myriad Genetics in 2018 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 93 increasing their positions, 82 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
260
Holders Change
+10
Holders Change %
+4%
% of All Funds
5.97%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
36
Increased
93
Reduced
82
Closed
23
Calls
$11.2M
Puts
$7.24M
Net Calls
+$3.93M
Net Calls Change
+$2.06M
Top Buyers
| 1 |
Goldman Sachs
New York
|
$46.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
$230M |
| 3 |
SI
Sensato Investors
San Francisco,
California
|
$16.4M |
| 4 |
BlackRock
New York
|
$307M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
$70.4M |
Top Sellers
| 1 |
Wells Fargo
San Francisco,
California
|
$6.29M |
| 2 |
D.E. Shaw & Co
New York
|
$124M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
$1.21M |
| 4 |
Two Sigma Advisers
New York
|
$287K |
| 5 |
Millennium Management
New York
|
$1.12M |
